November 1, 2017 FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMRI) as a prognostic biomarker for pre-dementia clinical trials for Alzheimer disease therapeutics Conrado, D.J., et al.; “FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMR
November 1, 2017 Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accelerating innovative Alzheimer disease treatments Arnerić, S.P., et al.; “Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accele
October 26, 2017 226th ENMC International Workshop: Towards Validated and Qualified Biomarkers for Therapy Development for Duchenne Muscular Dystrophy
October 24, 2017 US FDA Awards I-ACT for Children a Grant for Pediatric Medicines and Devices Network
October 18, 2017 C-Path and CDISC Announce Therapeutic Area User Guide for Duchenne Muscular Dystrophy October 18, 2017 TUCSON, Ariz., and AUSTIN, Texas – October 18, 2017 –Critical Path Institute (C-Path) and The
October 15, 2017 Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomarkers Conrado, D.J., et al.; “Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomar
October 15, 2017 Data sharing and standardization to expand a patient-level database of a regulatory-endorsed clinical trial simulator for Alzheimer disease (AD) Burton, J., et al.; “Data sharing and standardization to expand a patient-level database of a regulatory-endorsed clinical trial
